This trial will test a new drug, ARV-766, to see if it is safe and effective in treating men with prostate cancer that has spread and is resistant to hormone therapy.
7 Primary · 0 Secondary · Reporting Duration: 28 Days
Experimental Treatment
150 Total Participants · 3 Treatment Groups
Primary Treatment: ARV-766 · No Placebo Group · Phase 1 & 2
Age 18+ · Male Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:New York | 100.0% |
Met criteria | 100.0% |